PMID- 25310200
OWN - NLM
STAT- MEDLINE
DCOM- 20150728
LR  - 20141121
IS  - 1533-712X (Electronic)
IS  - 0271-0749 (Linking)
VI  - 34
IP  - 6
DP  - 2014 Dec
TI  - Comparison of physician-rating and self-rating scales for patients with major 
      depressive disorder.
PG  - 716-21
LID - 10.1097/JCP.0000000000000229 [doi]
AB  - Physician-rating scales remain the standard in antidepressant clinical trials. 
      The current study aimed to examine the discrepancies between physician-rating 
      scales and self-rating scales for symptoms and functioning, before and after 
      treatment, in newly hospitalized patients. A total of 131 acutely ill inpatients 
      with major depressive disorder were enrolled to receive 20 mg of fluoxetine daily 
      for 6 weeks. Symptom severity and functioning were assessed at baseline and again 
      at week 6. Symptom severity was rated using the 17-item Hamilton Depression 
      Rating Scale (HDRS-17) and the Zung Self-rating Depression Scale (ZDS). 
      Functioning was measured by the Global Assessment of Functioning (GAF) and the 
      Work and Social Adjustment Scale (WSAS). Pearson correlation coefficients (r) 
      between HDRS-17 and ZDS and between GAF and WSAS were calculated at week 0 and 
      week 6. Sensitivity to change was measured using effect sizes. One-hundred twelve 
      patients completed the 6-week trial. After 6 weeks of treatment, correlations 
      between HDRS-17 and ZDS or correlations between GAF and WSAS became larger from 
      baseline to end point. All correlations were statistically significant (P < 
      0.001). Effect sizes measured by physician-rating scales (ie, HDRS-17 and GAF) 
      were larger than by self-rating scales (ie, ZDS and WSAS). Correlations between 
      baseline physician-rating scale scores and self-rating scale scores improved 
      after 6 weeks of treatment. Physician-rating scales had larger effect sizes than 
      self-rating scales. Physician-rating scales were more sensitive in detecting 
      symptom or functional changes than self-rating scales.
FAU - Lin, Ching-Hua
AU  - Lin CH
AD  - From the *Kaohsiung Municipal Kai-Syuan Psychiatric Hospital; daggerDepartment of 
      Psychiatry, School of Medicine, College of Medicine, Kaohsiung Medical 
      University, Kaohsiung, Taiwan; and double daggerCenter for Innovative Technologies and Public 
      Health, Toronto, Canada.
FAU - Lu, Mei-Jou
AU  - Lu MJ
FAU - Wong, Julielynn
AU  - Wong J
FAU - Chen, Cheng-Chung
AU  - Chen CC
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - J Clin Psychopharmacol
JT  - Journal of clinical psychopharmacology
JID - 8109496
RN  - 0 (Antidepressive Agents, Second-Generation)
RN  - 01K63SUP8D (Fluoxetine)
SB  - IM
MH  - Adult
MH  - Antidepressive Agents, Second-Generation/therapeutic use
MH  - Depressive Disorder, Major/*diagnosis/drug therapy/*psychology
MH  - Female
MH  - Fluoxetine/therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Patient Participation/*psychology
MH  - Physician's Role/*psychology
MH  - Psychiatric Status Rating Scales/*standards
EDAT- 2014/10/14 06:00
MHDA- 2015/07/29 06:00
CRDT- 2014/10/14 06:00
PHST- 2014/10/14 06:00 [entrez]
PHST- 2014/10/14 06:00 [pubmed]
PHST- 2015/07/29 06:00 [medline]
AID - 10.1097/JCP.0000000000000229 [doi]
PST - ppublish
SO  - J Clin Psychopharmacol. 2014 Dec;34(6):716-21. doi: 10.1097/JCP.0000000000000229.